#United States #Washington D.C. #HistoIndex #Digital Pathology #FibroSIGHT

HistoIndex Debuts FibroSIGHT™ Plus at The Liver Meeting 2025

HistoIndex, a trailblazer in digital pathology tailored for chronic liver diseases, is gearing up to make a significant impact at The Liver Meeting® 2025 (TLM 2025), organized by the American Association for the Study of Liver Diseases (AASLD). The event is set to take place from November 7th to 11th, 2025, in Washington, D.C., and it promises to bring together top minds in hepatology.

This year marks a pivotal moment for HistoIndex as they transition from research-focused endeavors to offering clinical diagnostic solutions for Metabolic Dysfunction–Associated Steatohepatitis (MASH). A star attraction is the introduction of FibroSIGHT™ Plus, a Laboratory Developed Test (LDT) from their CLIA-accredited US laboratory. This innovative tool aims to enhance diagnostic accuracy through quantitative assessments of liver fibrosis, which is vital for managing MASH patients effectively.

Dr. Yukti Choudhury, HistoIndex's Chief Development Officer, expressed excitement over this development, emphasizing the necessity of implementing standardized measurements that could significantly elevate patient care in conventional settings. "Our goal is to offer precise liver diagnostics that can improve patient outcomes, especially for those dealing with MASH," Choudhury stated.

Scientific Contributions at TLM 2025

In addition to launching new services, HistoIndex plans a robust scientific outreach at TLM 2025, with an impressive lineup including one oral presentation and ten poster presentations. Among these, two posters are distinguished features highlighting significant advancements in the detection of fibrosis in advanced stages of MASH and cirrhosis from distinct drug trials. This data showcases how HistoIndex's advanced platform can effectively measure treatment efficacy in challenging cases, addressing critical gaps in MASH management.

An additional noteworthy oral presentation will focus on pioneering AI-based biopsy analysis efforts in an alpha-1 antitrypsin deficiency (AATD) medication trial, highlighting the broader applicability of their qFibrosis® technology beyond MASH. This integration of AI promises to enhance future fibrosis assessment and set standards for clinical practices.

Additionally, a late-breaking poster will unveil findings from the SYMMETRY Phase 2b trial, demonstrating how digital pathology and AI methodologies quantitatively evaluate reductions in fibrosis among compensated cirrhosis participants from MASH. Other exciting developments will include presentations outlining the capacity of AI systems to assess inflammation and microvasculature, thereby offering valuable insights into MASH-associated liver cancer models.

Dr. Dean Tai, HistoIndex's Chief Scientific Officer, remarked, "Our contributions to AASLD 2025 highlight the potential for our technology to initiate significant advancements in digital pathology assessments across a variety of liver diseases. From deciphering intricate treatment effects to providing insights across diverse contexts, our presentations will underline how our technology can enhance clinical practices."

Events and Networking Opportunities

Aside from the scientific endeavors, HistoIndex is hosting its customary breakfast meeting on November 8th, 2025, which spotlights collaborations with the National Institutes of Health (NIH) and Virginia Commonwealth University (VCU). This session will focus on utilizing Stain-free Second Harmonic Generation (SHG) and AI analytics, facilitating the identification of fibrosis trajectories in their efforts to streamline patient management strategies.

In celebration of progressing into clinical diagnostics with FibroSIGHT™ Plus, HistoIndex is organizing a dinner event aimed at enlightening hepatologists and gastroenterologists on the latest advancements in MASH diagnostics and AI-driven fibrosis assessment. Special guest speaker Dr. Naim Alkhouri will present comparative studies between AI-based analysis and traditional pathology assessments, providing a holistic context for the limitations of existing diagnostic methods.

The event is limited in capacity, thus early registration is encouraged for interested clinicians.

Booth #645 at TLM 2025

Attendees are invited to explore HistoIndex’s vibrant booth (#645) during the TLM, where they can delve into their pioneering technologies, particularly the newly launched FibroSIGHT™ Plus. The team will be on hand to discuss inquiries and explore potential collaborations in the field of liver diagnostics and beyond.

As a company founded in 2010, HistoIndex stands at the forefront of innovative pathology solutions, merging biophotonic technology with AI to revolutionize the assessments of fibrosis in biological tissues. Their continued commitment to improving clinical standards and drug development outcomes is evident in their dedication to research and pioneering advancements in the field of liver disease management.

For more information on HistoIndex's presence at The Liver Meeting 2025 and to discover more about FibroSIGHT™ Plus, please visit HistoIndex’s website.